Business Insider

American Medical Association (AMA) Grants Exosome Diagnostics a CPT PLA Specific to Its ExoDx® Prostate(IntelliScore) TestThe issuance of this CPT® Proprietary Laboratory ...

Cambridge, MA, April 26, 2017 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc. announced today that the American Medical Association (AMA) has issued a new CPT® Proprietary Laboratory Analyses (PLA) code ...
Business Wire

Clinical Data for World’s First Truly Non-Invasive Prostate Cancer Test Published in JAMA Oncology

ExoDx Prostate (IntelliScore) is a clinically validated, non-digital rectal exam (DRE) urine-based liquid biopsy test that predicts the presence of high-grade (Gleason score ≥7) prostate cancer for ...
Nasdaq

Bio-Techne Receives Approval To Offer The ExoDx(TM) Prostate Intelliscore(TM) (EPI) Test In New York State

MINNEAPOLIS, June 13, 2019 /PRNewswire/ -- Bio-Techne today announced that it has received a clinical laboratory permit from the New York State Department of Health to provide its ExoDx Prostate ...
Times Colonist

Your Good Health: New prostate cancer test snubbed by insurance

Dr. Keith Roach writes a medical question-and-answer column weekdays. Dear Dr. Roach: Due to an elevated PSA (5.3) my urologist recommended a fairly new test prior to deciding on a prostate biopsy.
Nasdaq

Bio-Techne Announces Publication of ExoDx™ Prostate (IntelliScore) EPI Test Clinical Utility Study

When implementing the ExoDx™ Prostate test in a real-world clinical setting, patients demonstrated improved compliance with the physician's recommendation to defer prostate biopsy when the test was ...
Business Insider

Bio-Techne Receives Approval To Offer The ExoDx™ Prostate Intelliscore™ (EPI) Test In New York State

MINNEAPOLIS, June 13, 2019 /PRNewswire/ -- Bio-Techne today announced that it has received a clinical laboratory permit from the New York State Department of Health to provide its ExoDx Prostate ...